Huei-Ting Tsai


GUMC Adjunct -- Appointment Pending
Assistant Professor of Oncology


Population Sciences
General profile

Alt. phone



Harris Building


Dr. Tsai is an Assistant Professor of Oncology at the Georgetown University Medical Center. At Lombardi, Dr. Tsai uses her expertise in pharmacoepidemiology and patient-centered outcomes research to examine the array of emerging therapies in cancer care to enhance quality of cancer care. Specifically, she has assessed cardiotoxicity of targeted therapy in breast and diffusive large B-cell lymphoma care and cardiac risk of antiangiogenesis agent use in colorectal cancer. She is also the PI for two federal grants where she investigates utilization and outcomes of intermittent hormonal therapy in prostate cancer. Dr. Tsai has published several peer-review articles in prestigious journals, including Journal of Clinical Oncology, Annals of Oncology, Urology, Breast Cancer Research and Treatment, Leukemia and Lymphoma, and the American Journal of Medical Genetics. Dr. Tsai served as a group instructor at the Georgetown University School of Medicine, teaching a course in Evidence-based Medicine that centers on the application of epidemiology methodology in evaluating medical literature. Dr. Tsai has joined several professional societies including the International Society of Pharmacoepidemiology and the International Society of Medical Decision Making.

Prior to her arrival at the Lombardi Comprehensive Cancer Center, Dr. Tsai was a postdoctoral fellow at the Division of Cancer Epidemiology and Genetics at the National Cancer Institute, where she won the Outstanding Research Paper Award from NIH for her prospective study on immune disruption in chronic lymphocytic leukemia. Dr. Tsai received her B.A. in Pharmacy and M.S. in Epidemiology from National Taiwan University. She pursued her Ph.D in Pharmacoepidemiology and Pharmacogenetics from the University of North Carolina at Chapel Hill, studying impact of genetic variation on risk of tardive dyskinesia, a long-term side effect of antipsychotic use, in chronic schizophrenia. She also participated in research projects with the World Health Organization on vaccine safety for polio eradication and with the Food and Drug Administration on monitoring drug safety in antipsychotics.


  • PhD (2007) University of North Carolina at Chapel Hill, Epidemiology
  • MS (2003) National Taiwan University, Epidemiology
  • BS (2000) National Taiwan University, Pharmacy